News

2024/05/30

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024

Read more
2024/05/30

Medivir to present at Redeye Growth Day

Read more
2024/05/23

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Read more

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.